---
title: "BeOne Medicines publishes Q2 clinical trials portfolio presentation detailing pipeline and study updates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294973584.md"
description: "BeOne Medicines released a Q2 clinical trials portfolio presentation highlighting its pipeline of 35+ assets. Key updates include Sonrotoclax approvals in the U.S. and China for hematologic malignancies, new Phase 1/Ib entries for BG-75202-102 and BON-110-101, and BGB-43395-302 entering pivotal trials for breast cancer."
datetime: "2026-08-05T13:16:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294973584.md)
  - [en](https://longbridge.com/en/news/294973584.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294973584.md)
generator: "portal-rs"
---

# BeOne Medicines publishes Q2 clinical trials portfolio presentation detailing pipeline and study updates

-   BeOne highlighted a pipeline snapshot with 35+ clinical or commercial-stage assets across hematology, solid tumors, inflammation and immunology. \* Sonrotoclax (BEQALZI) cited as approved in the U.S. for relapsed or refractory mantle cell lymphoma. \* Sonrotoclax also cited as approved in China for relapsed or refractory mantle cell lymphoma, relapsed or refractory chronic lymphocytic leukemia. \* Pipeline update flagged new Phase 1/Ib entries for BG-75202-102 in myeloid malignancies, BON-110-101 in solid tumors. \* Update flagged BGB-43395-302 as entering a pivotal trial in first-line HR+/HER2- breast cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)

## Related News & Research

- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)
- [BeOne Medicines and partners renew Brukinsa access programme for CLL](https://longbridge.com/en/news/296331290.md)
- [America Great Health reports interim data from ion-modified peptide adjunctive therapy observational study in solid tumors](https://longbridge.com/en/news/296824338.md)
- [Filament Health ships psilocybin candidate PEX010 for University of Washington Phase 2a cancer anxiety, depression trial](https://longbridge.com/en/news/296906129.md)
- [JAZZ: FDA approved Ziihera regimens for first-line HER2+ GEA, setting a new standard of care](https://longbridge.com/en/news/296933637.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**